CTI, or Pfizer’s Centers for Therapeutic Innovation, collaborates with leading academic medical centers and foundations nationwide in an effort to speed the translation of novel targets to the clinic. ADDF, with its mission to rapidly accelerate the discovery of drugs to prevent, treat, and cure Alzheimer’s disease, provides critical seed funding to leading scientists conducting breakthrough drug discovery and clinical research.

CTI, or Pfizer’s Centers for Therapeutic Innovation, collaborates with leading academic medical centers and foundations nationwide in an effort to speed the translation of novel targets to the clinic. ADDF, with its mission to rapidly accelerate the discovery of drugs to prevent, treat, and cure Alzheimer’s disease, provides critical seed funding to leading scientists conducting breakthrough drug discovery and clinical research.

Advantages to Collaborating with CTI
A partnership with CTI may include collaborative use of Pfizer’s technologies and compound library, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

Pre-proposal Submission Process
Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic approach. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

All researchers and clinicians whose work meets these criteria are invited to apply. Please submit pre-proposals to your Tech Transfer Office by October 7, 2016.

Please contact Lauren Friedman at lfriedman@alzdiscovery.org or Nader Halim at Nader.Halim@pfizer.com, as well as Manjula Donepudi at mdonepudi@mail.rockefeller.edu, with questions.

Alzheimer’s Disease (AD) Interest for Fall 2016
• Microvascular circulation and brain metabolism targets with validated link to AD
• Targets impacting neuroinflammation and neuroprotection
• Targets aimed at mechanisms associated with non-Ã© proteinopathies, such as tau and TDP-43
• Therapeutics against targets that can be modulated via intraparenchymal delivery (e.g. gene therapy approaches)
• Novel symptomatic agents for AD
• Targets linked to pathophysiology underlying traumatic brain injury
• Biomarker studies, projects without a target, and approaches directly targeted at Ã© protein are not appropriate for this request for proposals

What We Look For
• Validated therapeutic drug target: Strong link from targeted pathway to disease, and a tractable target, ideally supported by human data
• Strong project rationale: Demonstrated association between target biology and disease mechanism
• Novel drug targets with potential to lead to differentiated drugs
• Link between target pathway and human disease
• Ability to address unmet medical needs
• Feasibility: Tractable target, discovery/development plan